Actavis Completed The Acquisition Of Allergan
Actavis finished its acquisition of Allergan worth $70.5 billion. According to experts, the estimated annual revenue of the combined company will exceed $ 23 billion in 2015.
According to Brent Saunders, the executive director of Actavis, the activities of the combined company will cover approximately 100 countries. Earlier, he said that after merging Actavis will change its name to Allergan. However, in some markets Actavis will leave its old name.
The head of Actavis also said that the combined company intends to develop the direction of the development and research of new drugs. Every year 1.7 billion dollars will be sent on the development of new therapeutic agents.
"The procedure for purchasing Allergan has been completed and we will immediately begin to implement our plans for the comprehensive integration of the business to ensure stable growth of income of the combined company and its dynamic development in the field of global health," - said Brent Saunders.
- Roche Acquired The Developer Of Innovative Test Systems For Cancer Diagnosis
- Bristol-Myers Squibb announced the acquisition Flexus for $ 1.25 billion
- Valeant Has Increased The Cost Of Salix Acquisition